Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study

Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study

Abstract Background Sodium-glucose co-transporter 2 inhibitors (SGLT2 I) has cardiorenal protective properties and are recommended for patients with diabetes and established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Although cardiorenal complications are hig...

Full description

Bibliographic Details
Main Authors: Ngai Mui Ng, Yeung Shing Ng, Tsun Kit Chu, Phyllis Lau
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Primary Care
Subjects:
Type 2 diabetes
SGLT 2 inhibitors
Cardiovascular
Chronic kidney disease
Primary care
Qualitative study
Online Access:https://doi.org/10.1186/s12875-022-01928-z

Internet

https://doi.org/10.1186/s12875-022-01928-z

Similar Items